BR100 Increased By (0.11%)
BR30 Decreased By (-0.26%)
KSE100 Increased By (0.12%)
KSE30 Increased By (0.09%)
AGHA 7.79 Increased By ▲ 0.04 (0.52%)
BECO 5.23 Increased By ▲ 0.04 (0.77%)
BML 57.26 Decreased By ▼ -1.40 (-2.39%)
BOP 34.10 Increased By ▲ 0.41 (1.22%)
CNERGY 9.92 Decreased By ▼ -0.69 (-6.5%)
CSIL 5.35 Increased By ▲ 0.05 (0.94%)
FCCL 54.61 Increased By ▲ 0.87 (1.62%)
FFL 16.70 Increased By ▲ 0.24 (1.46%)
FNEL 1.24 Increased By ▲ 0.02 (1.64%)
KEL 7.42 Increased By ▲ 0.14 (1.92%)
KOSM 5.75 Increased By ▲ 0.11 (1.95%)
LOTCHEM 29.35 Decreased By ▼ -0.30 (-1.01%)
MLCF 94.35 Decreased By ▼ -2.01 (-2.09%)
NBP 202.70 Decreased By ▼ -0.83 (-0.41%)
NCPL 57.00 Increased By ▲ 0.15 (0.26%)
NPL 67.78 Increased By ▲ 0.47 (0.7%)
OGDC 316.40 Decreased By ▼ -1.82 (-0.57%)
PACE 10.64 Increased By ▲ 0.01 (0.09%)
PAEL 43.15 Increased By ▲ 1.38 (3.3%)
PIBTL 16.72 Decreased By ▼ -0.09 (-0.54%)
PPL 220.50 Increased By ▲ 0.33 (0.15%)
PRL 49.05 No Change ▼ 0.00 (0%)
PTC 70.98 Increased By ▲ 0.97 (1.39%)
SSGC 28.17 Decreased By ▼ -0.97 (-3.33%)
TBL 9.90 Increased By ▲ 0.13 (1.33%)
TELE 8.80 Decreased By ▼ -0.02 (-0.23%)
TPL 18.14 Increased By ▲ 0.97 (5.65%)
TPLP 13.40 Increased By ▲ 0.89 (7.11%)
TREET 22.75 Increased By ▲ 0.16 (0.71%)
TRG 60.30 Increased By ▲ 0.08 (0.13%)
World

EU regulator 'convinced' AstraZeneca jab benefits outweigh risks

  • The suspensions have provoked intense debate over whether it was prudent to put AstraZeneca inoculations on hold just as vaccination campaigns were beginning to gather pace.
Published Updated
By

THE HAGUE: The EU's medicines regulator said Tuesday it was "firmly convinced" the benefits of AstraZeneca's vaccine outweigh potential risks, insisting there was no evidence linking it to blood clots after several nations suspended the shot over health fears.

The suspensions have provoked intense debate over whether it was prudent to put AstraZeneca inoculations on hold just as vaccination campaigns were beginning to gather pace.

Experts at both the World Health Organization and the European Medicines Agency (EMA) met Tuesday to discuss the vaccine, with the European organisation expected to publish conclusions Thursday.

While millions of doses of the vaccine developed with Oxford University have been administered, small numbers of people have developed blood clots, prompting countries including the EU's three largest nations -- Germany, France and Italy -- to suspend injections.

The EMA insisted that countries should continue using the vaccine.

"We are still firmly convinced that the benefits of the AstraZeneca vaccine in preventing Covid-19 with its associated risk of hospitalisation and death outweigh the risk of these side effects," EMA chief Emer Cooke said Tuesday.

Cooke noted however that the regulator was "looking at adverse events associated with all vaccines".

France and Italy welcomed the news.

The preliminary statements from the EMA "are encouraging," read a joint statement from French President Emmanuel Macron and Italian Prime Minister Mario Draghi.

French Prime Minister Jean Castex vowed he would be vaccinated "very quickly" with the AstraZeneca vaccine to give the public confidence in the jab if it is ruled as safe by the EU medicines agency.

Castex also said that new restrictions could be put in place for the Paris region, such as the weekend lockdowns already imposed in the Nice and Calais regions.

"We are in a worrying and critical situation and, clearly, measures of the type that have been used in other parts of the territory are on the table," he told BFM TV in a live interview.

Comments

Comments are closed for this article.